In the last trading session, 5.11 million shares of the Akoya Biosciences Inc (NASDAQ:AKYA) were traded, and its beta was 1.22. Most recently the company’s share price was $2.35, and it changed around $0.11 or 4.91% from the last close, which brings the market valuation of the company to $116.47M. AKYA currently trades at a discount to its 52-week high of $6.31, offering almost -168.51% off that amount. The share price’s 52-week low was $1.88, which indicates that the current value has risen by an impressive 20.0% since then. We note from Akoya Biosciences Inc’s average daily trading volume that its 10-day average is 97070.0 shares, with the 3-month average coming to 152.35K.
Akoya Biosciences Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.25. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 5 recommended AKYA as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Akoya Biosciences Inc is expected to report earnings per share of -0.16 for the current quarter.
Akoya Biosciences Inc (NASDAQ:AKYA) trade information
Instantly AKYA has showed a green trend with a performance of 4.91% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.52 on recent trading dayincreased the stock’s daily price by 6.75%. The company’s shares are currently down -51.84% year-to-date, but still up 7.31% over the last five days. On the other hand, Akoya Biosciences Inc (NASDAQ:AKYA) is -25.87% down in the 30-day period. We can see from the shorts that 1.6 million shares have been sold at a short interest cover period of 13.43 day(s).
The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 41.25% from its current value. Analyst projections state that AKYA is forecast to be at a low of $3 and a high of $7.5.
Akoya Biosciences Inc (AKYA) estimates and forecasts
Akoya Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 7.31 percent over the past six months and at a 22.38% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be -15.24%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 21.47M in revenue for the current quarter. 5 analysts expect Akoya Biosciences Inc to make 19.77M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 26.49M and 18.35M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -18.93%. Forecasts for the next quarter put sales growth at 7.76%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -37.60%.
AKYA Dividends
Akoya Biosciences Inc’s next quarterly earnings report is expected to be released in January.
Akoya Biosciences Inc (NASDAQ:AKYA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.09% of Akoya Biosciences Inc shares, and 70.19% of them are in the hands of institutional investors. The stock currently has a share float of 78.94%. Akoya Biosciences Inc stock is held by 93.0 institutions, with BLUE WATER LIFE SCIENCE ADVISORS, LP being the largest institutional investor. By 2024-06-30, it held 9.5506% of the shares, which is about 4.7 million shares worth $10.99 million.
BLACKROCK INC., with 3.0534% or 1.5 million shares worth $3.51 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
